BioXcel Therapeutics is a clinical-stage biopharmaceutical company that utilizes artificial intelligence techniques to create revolutionary medicines in neuroscience and immuno-oncology. The average one-year price target for the company is $54.25, with a high of $78.75 and a low of $24.24.

According to HC Wainwright, the company is expected to report Earnings per share of ($1.77) for Q2 2023. The consensus estimate for BioXcel Therapeutics’ full-year earnings is ($6.09) per share.

BTAI Stock Performance on May 17, 2023: Stable Despite Negative Earnings Growth and Overvalued Valuation Ratios

On May 17, 2023, BTAI Stock opened at 27.30, slightly lower than its previous close of 27.56. The day’s range was between 26.50 and 27.32, with a volume of 4,517. The market cap of BTAI is $801.2M.

BTAI is a biotechnology company in the health technology sector. Its earnings growth has been negative, with a decline of 45.93% in the last year and 12.10% this year. However, the company is expected to have a significant earnings growth of 294.10% in the next five years.

BTAI’s P/E ratio is NM (not meaningful) due to negative earnings. Its price/sales ratio is 1,604.70, and its price/book ratio is 10.07.

On May 17, 2023, BTAI’s stock performance was relatively stable compared to its peers in the biotechnology industry.

BTAI’s next reporting date is on August 8, 2023, with an EPS forecast of -$1.66 for this quarter. The company reported an annual revenue of $375.0K and an annual profit of -$165.8M in the last year. Its net profit margin is -44,201.87%.

In conclusion, BTAI’s stock performance on May 17, 2023, was relatively stable compared to its peers in the biotechnology industry. The company’s negative earnings growth in the last year and this year is a concern, but its expected earnings growth in the next five years is significant. The company’s valuation ratios indicate that the stock is overvalued compared to its peers. Investors should monitor the company’s financial performance closely in the coming months.

BioXcel Therapeutics Inc (BTAI) Stock Analysis: Clinical-Stage Biopharmaceutical Company with Promising Pipeline for Neurological and Psychiatric Disorders

On May 17, 2023, BioXcel Therapeutics Inc (BTAI) closed at $27.32, with a median target of $47.00 among 10 analysts offering 12-month price forecasts. The high estimate is $75.00, and the low estimate is $24.00, with a consensus among 9 polled investment analysts to buy stock in the company. BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing therapies for neurological and psychiatric disorders, with a pipeline that includes BXCL501. The company’s current quarter earnings per share are -$1.66, with sales of $453.5K, and it is set to report earnings on August 08, 2023. Investors are optimistic about the company’s future, but should conduct their own research before making any decisions.

The post Analyst Reaffirms Buy Rating and Price Target for BioXcel Therapeutics appeared first on Best Stocks.